Chimeric Antigen by the Fusion of SARS-CoV-2 Receptor Binding Domain with the Extracellular Domain of Human CD154: A Promising Improved Vaccine Candidate.
Vaccines (Basel). 2022 Jun 3;10(6):897. doi: 10.3390/vaccines10060897.
Vaccines (Basel). 2022.
PMID: 35746505
Free PMC article.